Novartis Pharma B.V.
Location
Noord-Holland
Founded
1948-02-10
Website
Risk Signals
21159 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Drugs, Drug Proprietaries, and Druggists' Sundries), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Novartis Pharma B.V.
Live alerts from global media, monitored by Business Radar
2024-07-16 (tovima.gr)
Novartis, the hoods and the dance of money
The "gray" areas of the board and the financial prosecutor.
Read more
2024-06-27 (newsbreak.gr)
Black money in parties? Never!
Siemens has not given money to Tsoukatos to go to PASOK. Siemens has not given money to Mantelis as pre-election sponsorship. Kyriakos Mitsotakis
Read more
2024-06-27 (newsbreak.gr)
Black money in parties? Never!
Siemens has not given money to Tsoukatos to go to PASOK. Siemens has not given money to Mantelis as pre-election sponsorship. Kyriakos Mitsotakis
Read more
2024-06-25 (athensvoice.gr)
Georgiadis: In Justice against Polakis for the money in files
Adonis Georgiadis: In the Court against Polakis for the "money in envelopes" - The conflict between the two politicians on the occasion of the Kasselakis suspension
Read more
2023-04-09 (pharmaphorum.com)
Novartis, Alcon settle US bribery charges with £347 million payout
Novartis and eyecare spinout Alcon have agreed to settle bribery charges brought by the US federal authorities, focused on activities in Greece and other countries, for$ 347 million.Novartis’ Greek subsidiary Novartis Hellas and Alcon will pay around$ 234 million to the Department of Justice under
Read more
2018-10-04 (biopharma-reporter.com)
Insight: How Novartis built a ‘money-filled moat’ to market Kymriah
Novartis’ experimental marketing strategy, whereby the pharma giant used its scale to insure against failed CAR-T therapies, helped defend Kymriah from competition, says consultant.
Read more